Oscar Mukasa is the Chairperson of the HIV and AIDS Affairs Committee at the Tanzanian Parliament. A frequent speaker at international conferences due to his championship in raising awareness of the epidemics in his country and his region, Mukasa was a Manager at the National Council for people living with HIV. Oscar Mukasa holds a degree from the Netherlands Institute of Health Sciences.

Dr. Manal El-Sayed (Cairo, Egypt) is Professor of Pediatrics at Ain Shams University. She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal has worked with pediatric hematology and oncology teams at Ain Shams University, National Cancer Institute, and 57357 Children’s Cancer Hospital since 1990. Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitissince 2006. She contributed to the establishment of a nationwide network of 55 specialized liver centers that provided interferon therapy to 350,000 HCV-infected patients. Since 2014 when the NCCVH introduced the new direct-acting antiviral agents for HCV, more than 3million patients have been treated. Manal collaborated on the development of the national action plan for prevention andcontrol of viral hepatitis published in October 2014 with representatives from WHO, the U.S. Centers for Disease Control and Prevention (U.S. CDC), Pasteur Institute, and national stakeholders.In addition to co-supervising the nationwide mass screening program for adults and children reaching so far more than 56million people.Manal is also an active board member and secretary general of the Egyptian Liver Care Society, a non-governmental organization that offersfinancial assistance to patients receiving treatment for hepatitis or liver transplants. She has authored and co-authored numerous journal articles on hepatitis and liver diseases, and participated in the development of WHO’s HBV, HCV and diagnostic guidelines. From 2011-2015, Manal was Vice Chair of WHO’s Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt.She is also a board member of the European Study of Liver Disease International Liver Foundation since January 2018.In addition to being an oversight committee member of the EndHep2030 initiative since the beginning of 2019.

Karim Diop holds the position of General Secretary of the Regional Center for Research on infectious Diseases at Fann University Hospital, which brings together numerous researchers from ANRS, IRD,NIH, Washington University. He began his carrer in the early 2000s working with the first initiative on ART acces in Senegal (ISAARV), notably on the monitoring on the adherence of HIV patients and delivry ART . After his master , he joined the National HIV program where he has coordinated several public health project included one to strengthen national hospitals with Esther organization and another on strengthening the health system funded by the global fund . He has led initiatives developed for drug users , which has enabled the set up in 2015 of the first center for the management of addictions in West Africa (CEPIAD) . This 3 last years , he was invoveld in a regional program for enhance Harm reduction in Burkina Faso, Ivoiry Coast, Cabo Verde , Guinée Bissau and Senegal . Dr Karim Diop holds a Doctorate in Pharmacy from the University of Dakar . He also earned a Master in Public Health from ISPED Bordeaux , a university Diplom in Epidemiology from Bordeaux 2 University and university diplom in Addictology from Paris 13 University . Dr Diop is autor of several publications as autor or co autor in the fiel of HIV and drug users He belong to numerous learned international society ( RESAPSI , SAA, IAS)

Helgar is the Head of prevention program and specifically heading the Key Populations and AYP program Manager at the National AIDs and STI Control program and the East African Community HIV focal person for Kenya. She has the overall responsibility of steering and managing the national Key Populations Program. She is the chair of various technical working groups for Key populations and harm reduction. Ms Musyoki has over 23 years of clinical practice with 18 years’ experience in HIV programming and under her leadership, the country instituted the national key population program which houses the harm reduction program; developed and disseminated the key populations policy, various implementation guidelines and standard operating procedures; build the capacity of service providers at various levels; spearheaded the introduction of Needle and syringe program, 7 medically assisted therapy sites; instituted monitoring and evaluation mechanisms for the harm reduction program; commenced provision of hepatitis C treatment, among other key achievements. She has been involved in ground breaking researches, spearheaded numerous studies and has published widely on HIV and key populations among other topics in Kenya.